Novo Nordisk launches head-to-head trial with Eli Lilly as weight loss rivalry heats up
As Eli Lilly launches its newly approved weight loss med Zepbound to much fanfare, Novo Nordisk is tossing a next-gen candidate in the ring. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
